Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201210102 Principal Investigator: Welch, John
Title: Genomic Predictors of Decitabine Response in AML/MDS
Phase: II Disease Site: Myeloid and Monocytic Leukemia
Participating Site(s):
 
Main Campus
Map and Directions		 West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this research study is to identify genetic markers which will help us predict who will respond to treatment with a drug called decitabine and who will not. Typically, between 20 and 30% of patients with AML and MDS will achieve a complete response with decitabine, while the remaining patients will not. Right now, we have no way of predicting who will respond and who will not. We are also looking at what the best schedule of administration of decitabine might be.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)